A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs CEP 37251 (Primary) ; CEP 37251 (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Sponsors Cephalon
  • Most Recent Events

    • 11 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
    • 04 Nov 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Aug 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top